美国Nanogen   
Nanogen公司成立于1993年，位于加州San Diego，是一家微电子技术与分子生物学结合的芯片专利公司。在五年和威斯康辛大学医学院（the Medical College of Wisconsin）的合作中，Nanogen已经研制出了自动诊断仪器，这种仪器能快速的检测到引起败血症和肺炎的细菌或病毒
美国Nanogen生物技术公司（NGEN）2005年8月1日发布消息，国家传染疾病研究所（he National Institute of Allergy and Infectious Diseases，NIH）拨款$2,500,000给Nanogen公司，用于败血症和“社区获得性或群落性肺炎”类型的呼吸系统疾病(community-acquired pneumonia或CAP)的原位诊断研究。
2009年法国Elitech Group收购美国Nanogen
Nanogen has developed a strong product and proprietary technology base in advanced diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets – molecular diagnostics and rapid point-of-care testing. The role of diagnostics in healthcare is evolving rapidly buoyed by new and improved technologies that allow the advancement and decentralization of diagnostic applications. Products like those from Nanogen are quickening the pace toward personalized medicine. Both clinical laboratories and point-of-care providers are seeing strong validation of the contribution advanced diagnostic tests can have for the delivery of better, more personalized patient care. With its growing diagnostics product offering, Nanogen is poised to become a key player in this arena.

Nanogen’s products are used in multiple segments of the global IVD market - including applications in which testing is used as a prognostic indicator of disease and for ongoing monitoring of disease. Products include a broad menu of real-time PCR reagents and kits for DNA and RNA infectious disease targets as well as genotyping assays for key biomarkers in onco-hematology. The Company’s rapid tests for acute cardiac conditions and drugs of abuse are sold to customers requiring rapid results at or near the point of treatment such as emergency rooms.

All of Nanogen’s products are designed to improve the role diagnostics plays in improving individual patient care by providing more specific DNA-based results or by moving the diagnostic capability and decision closer to the patient. The strong intellectual property portfolio of advanced diagnostic technologies allows the company to bring unique solutions to the market. The IP portfolio includes: the MGB Eclipse® probes technology which is widely licensed and has proven to be a mainstay in helping to make real-time PCR a gold standard method in molecular biology research and diagnostic testing; and key patents for the reporting of multiple biomarkers in a rapid test format.